George Bazoukis1, Konstantinos P Letsas1, Gary Tse2, Katerina K Naka3, Panagiotis Korantzopoulos4, Evangelia Ntzani5, Konstantinos Vlachos1, Athanasios Saplaouras1, Eirini Pagkalidou6, Lampros K Michalis7, Antonios Sideris1, Michael Efremidis1. 1. Department of Cardiology, Electrophysiology Laboratory, Evangelismos General Hospital of Athens, Athens, Greece. 2. Department of Medicine and Therapeutics, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, SAR, P.R. China; Li Ka Shing Institute of Health Sciences, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, SAR, P.R. China. 3. Second Department of Cardiology, University of Ioannina, School of Medicine, Ioannina, Greece. 4. First Department of Cardiology, University of Ioannina, School of Medicine, Ioannina, Greece. 5. Department of Hygiene and Epidemiology, University of Ioannina, School of Medicine, Ioannina, Greece. 6. Department of Hygiene and Epidemiology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece. 7. Director of the Second Department of Cardiology, University of Ioannina, School of Medicine, Ioannina, Greece.
Abstract
BACKGROUND: Atrial fibrillation (AF) ablation is increasingly used in patients with reduced left ventricular ejection fraction (LVEF). The aim of the present study was to evaluate the long-term results of a single radiofrequency catheter ablation procedure in heart failure (HF) patients with AF. HYPOTHESIS: We tested the hypothesis that left atrial ablation is an effective therapeutic modality in patients with heart failure. METHODS: Our study included HF patients with LVEF <50% who underwent catheter ablation for AF at our department between January 2010 and March 2017. All patients underwent our institution's protocol for follow-up post-ablation. RESULTS: The study enrolled a total of 38 patients (mean age, 54.1 ± 12.2 years; 28 [73.7%] males; mean LVEF, 38.2% ± 6.3%). After a mean follow-up period of 38.2 months (range, 5-92 months), 28 patients (73.7%) were free from arrhythmia recurrence. In multivariate analysis, early arrhythmia recurrence (P = 0.03) and amiodarone antiarrhythmic drug administration (P = 0.003) remained independent predictors of arrhythmia recurrence. CONCLUSIONS: The main findings of this study are that (1) a single radiofrequency catheter ablation procedure is an effective and safe modality for AF in patients with concomitant HF; (2) after a mean 3.3 years of follow-up, 73.7% of HF patients remained in sinus rhythm; and (3) early arrhythmia recurrence was a significant predictor of arrhythmia recurrence after the blanking period.
BACKGROUND:Atrial fibrillation (AF) ablation is increasingly used in patients with reduced left ventricular ejection fraction (LVEF). The aim of the present study was to evaluate the long-term results of a single radiofrequency catheter ablation procedure in heart failure (HF) patients with AF. HYPOTHESIS: We tested the hypothesis that left atrial ablation is an effective therapeutic modality in patients with heart failure. METHODS: Our study included HF patients with LVEF <50% who underwent catheter ablation for AF at our department between January 2010 and March 2017. All patients underwent our institution's protocol for follow-up post-ablation. RESULTS: The study enrolled a total of 38 patients (mean age, 54.1 ± 12.2 years; 28 [73.7%] males; mean LVEF, 38.2% ± 6.3%). After a mean follow-up period of 38.2 months (range, 5-92 months), 28 patients (73.7%) were free from arrhythmia recurrence. In multivariate analysis, early arrhythmia recurrence (P = 0.03) and amiodarone antiarrhythmic drug administration (P = 0.003) remained independent predictors of arrhythmia recurrence. CONCLUSIONS: The main findings of this study are that (1) a single radiofrequency catheter ablation procedure is an effective and safe modality for AF in patients with concomitant HF; (2) after a mean 3.3 years of follow-up, 73.7% of HF patients remained in sinus rhythm; and (3) early arrhythmia recurrence was a significant predictor of arrhythmia recurrence after the blanking period.
Authors: Santosh K Padala; Sampath Gunda; Parikshit S Sharma; Le Kang; Jayanthi N Koneru; Kenneth A Ellenbogen Journal: Heart Rhythm Date: 2017-05-04 Impact factor: 6.343
Authors: F D'Ascenzo; A Corleto; G Biondi-Zoccai; M Anselmino; F Ferraris; L di Biase; A Natale; R J Hunter; R J Schilling; S Miyazaki; H Tada; K Aonuma; L Yenn-Jiang; H Tao; C Ma; D Packer; S Hammill; F Gaita Journal: Int J Cardiol Date: 2012-05-22 Impact factor: 4.164
Authors: Yoko Miyasaka; Marion E Barnes; Kent R Bailey; Stephen S Cha; Bernard J Gersh; James B Seward; Teresa S M Tsang Journal: J Am Coll Cardiol Date: 2007-02-16 Impact factor: 24.094
Authors: Victoria Jacobs; Heidi T May; Tami L Bair; Brian G Crandall; Michael Cutler; John D Day; J Peter Weiss; Jeffrey S Osborn; Joseph B Muhlestein; Jeffrey L Anderson; Charles Mallender; T Jared Bunch Journal: Heart Rhythm Date: 2014-12-26 Impact factor: 6.343
Authors: Hakan Oral; Bradley P Knight; Mehmet Ozaydin; Hiroshi Tada; Aman Chugh; Sohail Hassan; Christoph Scharf; Steve W K Lai; Radmira Greenstein; Frank Pelosi; S Adam Strickberger; Fred Morady Journal: J Am Coll Cardiol Date: 2002-07-03 Impact factor: 24.094
Authors: Erica Zado; David J Callans; Michael Riley; Mathew Hutchinson; Fermin Garcia; Rupa Bala; David Lin; Joshua Cooper; Ralph Verdino; Andrea M Russo; Sanjay Dixit; Edward Gerstenfeld; Francis E Marchlinski Journal: J Cardiovasc Electrophysiol Date: 2008-05-05
Authors: Ka Hou Christien Li; Tian Sang; Cheng Chan; Mengqi Gong; Yingzhi Liu; Aaron Jesuthasan; Guangping Li; Tong Liu; Michael H S Lam; William Kk Wu; Matthew T V Chan; Fang-Zhou Liu; Cheng Chen; Jeffery Ho; Yunlong Xia; Gary Tse Journal: Heart Asia Date: 2019-08-14